An open-label, randomized, phase 3 study of the efficacy and safety of antithrombin gamma in patients with sepsis-induced disseminated intravascular coagulation syndrome

Table 2 Primary endpoint: presence or absence of DIC recovery on day 6 (or at withdrawal)

AT antithrombin, CI confidence interval, DIC disseminated intravascular coagulation, pAT plasma-derived antithrombin
^aThe protocol was amended to include all patients with AT activity ≤ 70% so that the patient population would more accurately reflect the intended clinical use. The (adjusted) DIC recovery rate and its 95% CI were calculated for each treatment group after stratification (using the Woolson–Bean method) by the AT activity (< 50%, 50–70%) at study enrollment

ISSN: 2052-0492